SIGA Technologies has received approval from the EMA to market tecovirimat in all EU member states, as well as Norway, Iceland and Liechtenstein. The drug is indicated for the treatment of smallpox, monkeypox, cowpox and complications after smallpox vaccination.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept